Homology Medicines (NASDAQ:FIXX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “

FIXX has been the topic of a number of other research reports. Evercore ISI started coverage on Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price target on the stock. ValuEngine upgraded Alleghany from a “hold” rating to a “buy” rating in a research report on Friday, April 19th. Finally, HC Wainwright set a $4.00 price target on Uranium Energy and gave the company a “buy” rating in a research report on Tuesday, June 11th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Homology Medicines presently has a consensus rating of “Buy” and a consensus target price of $29.10.

Shares of FIXX stock traded up $0.98 on Tuesday, reaching $20.58. The company’s stock had a trading volume of 132,740 shares, compared to its average volume of 221,334. Homology Medicines has a 12-month low of $15.07 and a 12-month high of $31.80. The firm has a market cap of $859.10 million, a P/E ratio of -10.29 and a beta of 0.17. The company has a 50 day simple moving average of $19.33.

Homology Medicines (NASDAQ:FIXX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.11). Homology Medicines had a negative return on equity of 34.90% and a negative net margin of 2,253.08%. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $1.00 million. Research analysts anticipate that Homology Medicines will post -2.32 EPS for the current year.

In other Homology Medicines news, insider Albert Seymour sold 9,300 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.90, for a total transaction of $185,070.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO W Bradford Smith sold 6,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.94, for a total value of $119,640.00. The disclosure for this sale can be found here. Insiders have sold 686,600 shares of company stock worth $14,606,534 in the last 90 days. Company insiders own 33.40% of the company’s stock.

Several large investors have recently made changes to their positions in the company. RTW Investments LP grew its stake in shares of Homology Medicines by 275.6% during the fourth quarter. RTW Investments LP now owns 1,633,491 shares of the company’s stock valued at $36,525,000 after buying an additional 1,198,574 shares during the last quarter. BlackRock Inc. grew its stake in shares of Homology Medicines by 134.3% during the fourth quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock valued at $32,656,000 after buying an additional 837,099 shares during the last quarter. Northern Trust Corp grew its stake in shares of Homology Medicines by 49.6% during the fourth quarter. Northern Trust Corp now owns 181,361 shares of the company’s stock valued at $4,055,000 after buying an additional 60,163 shares during the last quarter. Global Thematic Partners LLC grew its stake in shares of Homology Medicines by 22.7% during the first quarter. Global Thematic Partners LLC now owns 165,327 shares of the company’s stock valued at $4,585,000 after buying an additional 30,551 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Homology Medicines by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 153,033 shares of the company’s stock valued at $3,421,000 after buying an additional 41,972 shares during the last quarter. 52.87% of the stock is currently owned by hedge funds and other institutional investors.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Further Reading: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.